EUVIMEDEUVIMED entdecken
Open Access

ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer

Po-Li Wei, Chien-Yu Huang, Cheng-Chin Lee, Uyanga Batzorig, Kuei-Yen Tsai, Yu-Jia Chang

International Journal of Medical Sciences · 27.07.2026 · 23 (9) · 2835-2846

DOI: 10.7150/ijms.133461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Medical Sciences, erschienen am 27.07.2026. Verfasst von Po-Li Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. Hauptthemen laut MEDLINE: Oxaliplatin, Colorectal Neoplasms, Drug Resistance, Neoplasm, Aldehyde Dehydrogenase, Mitochondrial. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemoresistance remains a major limitation in the treatment of colorectal cancer (CRC), particularly in tumors harboring TP53 mutations. Although aldehyde dehydrogenase 2 (ALDH2) has been implicated in cancer biology, its role in regulating platinum sensitivity and the underlying molecular context remain incompletely understood.

Methods

Public transcriptomic and proteomic datasets (TCGA, GEO, CPTAC) were analyzed to evaluate ALDH2 expression patterns, prognostic relevance, and associations with chemotherapy response in CRC. Functional studies were performed in p53-mutant and p53-wild-type CRC cell lines using pharmacological inhibition and genetic silencing of ALDH2, complemented by p53 knockout and reconstitution approaches. Downstream signaling was interrogated by gene set enrichment analysis, quantitative PCR, and pharmacological inhibition of phosphodiesterase 4B (PDE4B). Oxaliplatin sensitivity was assessed using cell viability and apoptosis assays.

Results

ALDH2 expression was significantly reduced in CRC tissues and was associated with unfavorable clinical outcomes and diminished oxaliplatin responsiveness. Functional experiments revealed that inhibition or knockdown of ALDH2 selectively induced oxaliplatin resistance in p53-mutant CRC cells, while p53-wild-type cells were largely unaffected. Mechanistically, loss of ALDH2 led to upregulation of PDE4B in a p53 status-dependent manner. Elevated PDE4B expression correlated with chemoresistance and poor recurrence-free survival in patients with p53-mutant CRC. Importantly, pharmacological inhibition of PDE4B using the clinically approved drug roflumilast effectively restored oxaliplatin-induced apoptosis and reversed chemoresistance in ALDH2-deficient, p53-mutant CRC cells.

Conclusions

This study identifies a previously unrecognized, p53 status-dependent ALDH2-PDE4B regulatory axis that governs oxaliplatin sensitivity in colorectal cancer. Our findings highlight ALDH2 as a potential predictive biomarker for oxaliplatin response in p53-mutant CRC and suggest that targeting PDE4B may represent a promising strategy to overcome chemoresistance in this molecular context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinColorectal NeoplasmsDrug Resistance, NeoplasmAldehyde Dehydrogenase, MitochondrialTumor Suppressor Protein p53Cyclic Nucleotide Phosphodiesterases, Type 4HumansGene Expression Regulation, NeoplasticCell Line, TumorMutationApoptosisAntineoplastic AgentsFemale

Stichwörter der Autor:innen

Aldehyde dehydrogenase 2Chemoresistancep53-mutantp53-mutant colorectal cancerp53-wild-type

Substanzen

OxaliplatinAldehyde Dehydrogenase, MitochondrialTumor Suppressor Protein p53Cyclic Nucleotide Phosphodiesterases, Type 4ALDH2 protein, humanTP53 protein, humanPDE4B protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.
  • Cancer Research Center and Translational Laboratory, Department of Medical Research, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.
  • Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei 11031, Taiwan.
  • School of Medicine, National Tsing Hua University, Hsinchu 300044, Taiwan.
  • Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 300044, Taiwan.

Zitieren

APA

Wei, P. L., Huang, C. Y., Lee, C. C., Batzorig, U., Tsai, K. Y., & Chang, Y. J. (2026). ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer. International Journal of Medical Sciences, 23(9), 2835-2846. https://doi.org/10.7150/ijms.133461

Vancouver

Wei PL, Huang CY, Lee CC, Batzorig U, Tsai KY, Chang YJ. ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer. International Journal of Medical Sciences. 2026;23(9):2835-2846. doi:10.7150/ijms.133461

BibTeX
@article{Wei2026,
  author = {Wei, Po-Li and Huang, Chien-Yu and Lee, Cheng-Chin and Batzorig, Uyanga and Tsai, Kuei-Yen and Chang, Yu-Jia},
  title = {ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer},
  journal = {International Journal of Medical Sciences},
  year = {2026},
  volume = {23},
  number = {9},
  pages = {2835--2846},
  doi = {10.7150/ijms.133461}
}
Kostenlos starten →